Lung Cancer Clinical Trial
Official title:
Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies
Verified date | January 2020 |
Source | University of Kentucky |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to find an optimal smoking cessation strategy in patients undergoing therapy for lung and head and neck cancers at selected cancer centers in Kentucky by delivering high quality smoking cessation to all enrolled patients. This study will also examine the feasibility of routinely implementing an array of smoking cessation strategies for this patient population.
Status | Completed |
Enrollment | 93 |
Est. completion date | May 15, 2019 |
Est. primary completion date | May 15, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients must be = 18 years of age. - Patient with newly diagnosed or recurrent, histologic diagnosis of any of the following tobacco related malignancies: 1. Lung or Bronchus cancer or Head & Neck, cancers (all sites). 2. Esophagus, Stomach, Pancreas, Kidney, Urinary Bladder, Colon, Rectum, Cervix, Vulvar, Vaginal 3. Carcinoma in situ undergoing definitive surgical resection or treatment (ex: radiation of the larynx, and gynecologic tract hysterectomy, vulvectomy - except gynecologic patients undergoing ablative or local excisional therapies [laser ablation,cervical conization, LEEP]. - Having smoked at least 1 cigarette within 4 weeks of study enrollment. - Having at least a 10-pack year history of cigarette smoking. - Having smoked at least one cigarette within 1 month of cancer diagnosis. - Life expectancy is greater than 1 year. - Patient has an AUDIT score of < 10. - Patient has ECOG Performance Status of <=2. - Patients must have the ability to understand and the willingness to provide signed written informed consent document. Exclusion Criteria: - Known allergy attributed to bupropion, varenicline, transdermal or lozenge nicotine. - History of suicide attempt or preparation for attempt within the past 10 years. - C-SRSS Baseline/Screening: 1. Patient response of "Yes" to any question except question 1. 2. Patient response of "Yes" to any question in column one (lifetime), except question 1, is not exclusionary unless judged by the investigator to be significant in ideation, intensity, behavior or attempts, and precludes participation. - Hospitalized for psychiatric illness within the past two years. - History of Bipolar disorder. - Currently taking Bupropion for depression. - Patient has taken monoamine oxidase inhibitors (MAOI) in the past two weeks. - History of eating disorder such as anorexia or bulimia. - Active widespread skin disorders such as psoriasis, chronic urticarial or dermatitis - History of epilepsy or seizure disorder. - Active severe kidney or liver disease. - Women must not be pregnant or lactating. Women of reproductive-potential must have negative serum or urine pregnancy test within 7 days prior to study enrollment and agree to use method of contraception during and for 30 days following last cessation drug dose. - Patients within three months of a myocardial infarction. - Patients with unstable angina or serious arrhythmia. - Patients with psychiatric disability judged by the investigator to be clinically significant so as to preclude informed consent or compliance with drug intake. - Patient taking varenicline or bupropion within one month of study enrollment. - Participation in any other investigational drug study within 4 weeks of study enrollment. - Currently enrolled in other professional tobacco cessation therapeutic intervention. - Enrollment in a concurrent cancer therapeutic trial will require prior review and approval by the study site PI to determine that there are no drug interactions concerns. |
Country | Name | City | State |
---|---|---|---|
United States | King's Daughters Medical Center | Ashland | Kentucky |
United States | Hardin Memorial Health Cancer Care Center | Elizabethtown | Kentucky |
United States | ARH Cancer Center | Hazard | Kentucky |
United States | Kentucky Cancer Clinic | Hazard | Kentucky |
United States | St. Mary's Medical Center | Huntington | West Virginia |
United States | Lexington Veterans Affair Medical Center | Lexington | Kentucky |
United States | University Of Kentucky, Markey Cancer Center | Lexington | Kentucky |
United States | University of Louisville, James Graham Brown Cancer Center | Louisville | Kentucky |
United States | St. Claire Regional Medical Center | Morehead | Kentucky |
United States | Owensboro Health | Owensboro | Kentucky |
Lead Sponsor | Collaborator |
---|---|
University of Kentucky | Kentucky Lung Cancer Research Program |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cigarette use | Seven day point prevalence of cigarette use confirmed with CO testing at eight weeks. | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|